Emergent Biosolutions (EBS) said Wednesday it entered into a new credit agreement for an asset-based revolving loan facility, effective Sept. 30, with Wells Fargo Bank as administrative agent.
The credit agreement provides for revolving loan commitments of up to $100 million with a maturity date of 2029, the company said.
As of Sept. 30, Emergent said it had a cash balance of $150 million and undrawn access to $100 million under the loan facility.
Price: 8.48, Change: +0.01, Percent Change: +0.12
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。